Table 2.

Analysis of the DRB1-DQA1-DQB1 second alleles in heterozygous HLA DRB1*03/x (DR3-DQ2) and DRB1*04*/x (DR4-DQ8) patients and controls, carrying one high-risk allele. Data were separately analysed for HLA DRB1*03/x (DR3-DQ2) and DRB1*04/x (DR4-DQ8) heterozygous groups.

Patients with DRB1*03/x
DRB1*	DQA1*	DQB1*	Controls	T1D Patients	Odds Ratio (CI)	p
			n (%)	n (%)
01:01	01:01	05:01	359 (10.5)	11 (29.7)	1.29 (0.62; 2.65)	0.447
07:01	02:01	02:02	332 (9.7)	2 (5.4)	0.19 (0.05; 0.72)	0.009
08:01	04:01/02	04:02	105 (3.1)	5 (13.5)	2.01 (0.83; 4.98)	0.188
09:01	03:02	03:03	23 (0.7)	4 (10.8)	7.55 (2.68; 22.77)	0.007
12:01	05:05	03:01	94 (2.7)	2 (5.4)	0.83 (0.19; 3.18)	0.999
13:01	01:03	06:03	281 (8.2)	2 (5.4)	0.24 (0.06; 0.89)	0.032
13:02	01:02	06:04	142 (4.1)	3 (8.1)	0.81 (0.26; 2.41)	0.999
16:01	01:02	05:02	120 (3.5)	8 (21.6)	3.07 (1.44; 6.69)	0.011
others			1456 (42.5)
Patients with DRB1*04/x
DRB1*	DQA1*	DQB1*	Controls	T1D Patients	Odds Ratio (CI)	p
			n (%)	n (%)
01:01	01:01	05:01	170 (11.1)	15 (25.0)	2.68 (1.44; 4.85)	0.003
01:02	01:01	05:01	25 (1.6)	2 (3.3)	2.08 (0,48; 7.88)	0.270
04:01	03:02	03:01	44 (2.9)	2 (3.3)	1.17 (0.27; 4.50)	0.691
07:01	02:01	02:02	124 (8.1)	3 (5.0)	0.59 (0.19; 1.80)	0.624
07:01	02:01	03:03	59 (3.8)	1 (1.7)	0.42 (0.04; 2.38)	0.725
08:01	04:01/02	04:02	67 (4.4)	14 (23.3)	6.66 (3.55; 12.56)	<0.001
08:04	04:01	04:02	3 (0.2)	1 (1.7)	8.65 (0.66; 58.49)	0.142
11:01	05:05	03:01	151 (9.8)	4 (6.7)	0.65 (0.25; 1.77)	0.512
11:03	05:05	03:01	15 (1.0)	1 (1.7)	17.16 (2.98; 84.83)	0.014
12:01	05:05	03:01	26 (1.7)	1 (1.7)	1.97 (0.45; 7.38)	0.291
13:01	01:03	06:03	130 (8.5)	5 (8.3)	0.98 (0.41; 2.38)	0.999
13:02	01:02	06:04	64 (4.2)	6 (10.0)	2.55 (1.13; 5.92)	0.044
13:03	05:05	03:01	18 (1.2)	1 (1.7)	1.43 (0.13; 8.31)	0.520
16:01	01:02	05:02	59 (2.8)	4 (6.7)	1.79 (0.67; 4.78)	0.295
others			397 (25.9%)